Nanoscope Therapeutics Inc., provides a commercial update on MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy.
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy.